Skip to content
BIO joins Coalition for Trust in Health & Science
On March 2, 2023, the Biotechnology Innovation Organization (BIO) and 50 other national ...
Read More
Fund tracing shows that a reform of 340B is long overdue
Questions regarding the significant profits made by the 340B Drug Pricing Program were ...
Read More
FDA’s advisory panel backs GSK’s RSV vaccine
On Feb. 28, 2023, the U.S. Food and Drug Administration (FDA) Vaccines and ...
Read More
U.S. Chamber’s IP Index highlights progress and new threats
The 11th International IP Index was published by the U.S. Chamber of Commerce, ...
Read More
Acceligen develops new breed of pigs resistant to PRRS
Acceligen has developed a breed of pigs resistant to the devastating disease Porcine ...
Read More
FDA panel recommends Pfizer RSV vaccine for older adults
The Pfizer RSV vaccine candidate for adults over 60 has been recommended by ...
Read More
EDITORS' CHOICE
BIO CEO testifies in hearing highlighting PBMs’ impact on drug prices
Pharmacy benefit managers (PBMs) were identified as a major driver behind higher prescription drug costs in a congressional hearing that featured testimony from BIO President ...
Read More
LATEST NEWS
BIO Events
BIG Summit panel breaks down risks and opportunities coming out of DC
Washington’s healthcare policy landscape is constantly evolving, and 2026 is shaping up to be another consequential year for the biotech industry. Some developments are positive, ...
BIO's View
The hidden layer of PBMs: What a recent investigation reveals
With health care affordability a top concern for many Americans, pharmacy benefit managers (PBMs) continue to stand at the center of the debate. Working with ...
BIO's View
Nearly half of Americans say insurers’ rules on access delayed, denied, or altered care
Americans are frustrated with the health care system for two reasons. First, it costs too much. But—second—it provides too little. While most of the dialogue ...
BIO Events
BIG Summit: Experts see signs of M&A momentum in 2026
We could be in for another big year of biotech M&A. A busy 2025, in both licensing and M&A in biopharma, saw over 4,000 deals ...
BIO Events
BIG Summit: Seeking opportunities while navigating risks of global trade
China is becoming an increasingly influential player in the global biotech market. More than a third of U.S. licensing deals this year have involved assets ...
HEALTH
Welcome, John F. Crowley!
Get to know John F. Crowley, the new President and CEO of the Biotechnology Innovation Organization (BIO), in our exclusive interview.
Federal Policy
State Policy
Charlotte emerging as a global leader in health care innovation and med tech
Historically, Charlotte has been recognized as a major U.S. financial hub. Now, the city is making significant strides in another ...
Read More
International
Bio's View
The hidden layer of PBMs: What a recent investigation reveals
With health care affordability a top concern for many Americans, pharmacy benefit managers (PBMs) continue to stand at the center ...
Read More
